MARKER THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
MARKER THERAPEUTICS, INC. (MRKR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$5.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.40M.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$5.50M.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$3.79M.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$5.38M.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$2.15M, a 152.67% decline from fiscal 2024.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $4.08M, a 22.58% increase from fiscal 2023.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $3.33M.
- MARKER THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$31.72M, a 243.22% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.12M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$1.40M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$2.15M 10-K · filed 2026-03-18 | |||
| 2025-09-30 | -$249.49K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$7.38M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$5.50M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $4.08M 10-K · filed 2026-03-18 | |||
| 2024-09-30 | -$6.11M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$7.31M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$3.79M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $3.33M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $5.69M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $6.34M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$5.38M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$31.72M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | -$25.42M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$17.68M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$14.68M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $22.14M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $27.35M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $35.87M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $43.16M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | -$22.55M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | -$16.95M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$11.78M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | -$3.65M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$17.84M 10-K · filed 2021-03-09 | |||
| 2019-09-30 | -$13.27M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$8.30M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$4.04M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $56.62M 10-K · filed 2020-03-12 | |||
| 2018-09-30 | -$835.02K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $2.65M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |